Non-alcoholic fatty liver disease (NAFLD) has emerged pandemically across the globe and
particularly affects patients with obesity and type 2 diabetes. NAFLD is a complex systemic …

The NLRP3 inflammasome is a multimeric cytosolic protein complex that assembles in
response to cellular perturbations. This assembly leads to the activation of caspase-1, which …

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease
worldwide. NAFLD begins as a relatively benign hepatic steatosis which can evolve to non …

The involvement of inflammasomes in the proinflammatory response observed in chronic
liver diseases, such as alcohol-associated liver disease (ALD) and nonalcoholic fatty liver …

Obesity is one of the major health burdens of the 21st century as it contributes to the growing
prevalence of its related comorbidities, including insulin resistance and type 2 diabetes …

Low-grade inflammation is the hallmark of metabolic disorders such as obesity, type 2
diabetes and nonalcoholic fatty liver disease. Emerging evidence indicates that these …

Continuously rising trends in obesity-related malignancies render this disease spectrum a
public health priority. Worldwide, the burden of cancer attributable to obesity, expressed as …

There has been a rise in the prevalence of nonalcoholic fatty liver disease (NAFLD),
paralleling a worldwide increase in diabetes and metabolic syndrome. NAFLD, a continuum …

Inflammasomes are protein complexes of the innate immune system that initiate
inflammation in response to either exogenous pathogens or endogenous danger signals …

Interleukin (IL)-18 was originally discovered as a factor that enhanced IFN-γ production from
anti-CD3-stimulated Th1 cells, especially in the presence of IL-12. Upon stimulation with Ag …